Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SML2988

Sigma-Aldrich

Tat-NR2B9c trifluoroacetate

≥95% (HPLC)

Synonym(s):

NA-1, trifluoroacetate salt, Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val, trifluoroacetate salt, YGRKKRRQRRR-KLSSIESDV, trifluoroacetate salt

Sign Into View Organizational & Contract Pricing

Select a Size

1 MG
$72.79
5 MG
$316.00

$72.79

List Price$77.80Save 6%
Web-Only Promotion

Available to ship onApril 18, 2025Details


Request a Bulk Order

Select a Size

Change View
1 MG
$72.79
5 MG
$316.00

About This Item

Empirical Formula (Hill Notation):
C105H188N42O30 · xC2HF3O2
CAS Number:
Molecular Weight:
2518.88 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77

$72.79

List Price$77.80Save 6%
Web-Only Promotion

Available to ship onApril 18, 2025Details


Request a Bulk Order

Quality Level

assay

≥95% (HPLC)

form

powder

color

white to off-white

storage temp.

−20°C

Biochem/physiol Actions

NMDAR-PSD-95 interaction blocking peptide with neuroprotective efficacy in vitro and in vivo.
Tat-NR2B9c (NA-1) is a 20-mer peptide composed of a membrane-permeant HIV-1 Tat protein transduction domain sequence (a.a. 47-57) N-terminal to the NMDA receptor (NMDAR) GluN2B carboxyl tail sequence KLSSIESDV that blocks intracellular NMDAR-PSD-95 interaction-induced neurotoxic signaling without affecting NMDAR-mediated synaptic activity or calcium influx. NA-1 protects cultured cortical neurons from NMDA excitotoxicity (50 nM; 20/40/100 μM NMDA) and reduces focal ischemic brain damage in rats in vivo (3 μmol/kg iv. bolus 1 hr post MCAO onset).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Luka R Srejic et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 33(12), 1937-1943 (2013-09-12)
Since the most significant ischemic sequelae occur within hours of stroke, it is necessary to understand how neuronal function changes during this time. While histologic and behavioral models show the extent of stroke-related damage, only in vivo recordings can illustrate
Yanting Chen et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 35(5), 739-742 (2015-02-12)
The Tat-NR2B9c peptide has shown clinical efficacy as a neuroprotective agent in acute stroke. Tat-NR2B9c is designed to prevent nitric oxide (NO) production by preventing postsynaptic density protein 95 (PSD-95) binding to N-methyl-D-aspartate (NMDA) receptors and neuronal nitric oxide synthase;
Diego Milani et al.
Neuroscience research, 114, 9-15 (2016-09-19)
We examined the efficacy of R18 in a transient MCAO model and compared its effectiveness to the well-characterized neuroprotective NA-1 peptide. R18 and NA-1 peptides were administered intravenously (30, 100, 300, 1000nmol/kg), 60min after the onset of 90min of MCAO.
Yue Liu et al.
Anesthesia and analgesia, 118(6), 1345-1354 (2014-05-21)
N-methyl-D-aspartate receptor (NMDARs)-dependent central sensitization plays an important role in cancer pain. Binding of NMDAR subunit 2B (NR2B) by postsynaptic density protein-95 (PSD-95) can couple NMDAR activity to intracellular enzymes, such as neuronal nitric oxide synthase (nNOS), facilitate downstream signaling
Lucy M Teves et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 36(3), 555-561 (2015-12-15)
Tat-NR2B9c, a clinical-stage stroke neuroprotectant validated in rats and primates, was recently deemed ineffective in mice. To evaluate this discrepancy, we conducted studies in mice subjected to temporary middle cerebral artery occlusion (tMCAO) for either 30 or 60 min according to

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service